1.The Model for End-Stage Liver Disease Score-Based System Predicts Short Term Mortality Better Than the Current Child-Turcotte-Pugh Score-Based Allocation System during Waiting for Deceased Liver Transplantation.
Geun HONG ; Kwang Woong LEE ; Sukwon SUH ; Tae YOO ; Hyeyoung KIM ; Min Su PARK ; Youngrok CHOI ; Nam Joon YI ; Kyung Suk SUH
Journal of Korean Medical Science 2013;28(8):1207-1212
To adopt the model for end-stage liver disease (MELD) score-based system in Korea, the feasibility should be evaluated by analysis of Korean database. The aim of this study was to investigate the feasibility of the MELD score-based system compared with the current Child-Turcotte-Pugh (CTP) based-system and to suggest adequate cut-off to stratify waiting list mortality among Korean population. We included 788 adult patients listed in waiting list in Seoul National University Hospital from January 2008 to May 2011. The short-term survival until 6 months after registration was evaluated. Two hundred forty six (31.2%) patients underwent live donor liver transplantation and 353 (44.8%) patients were still waiting and 121 (15.4%) patients were dropped out due to death. Significant difference was observed when MELD score 24 and 31 were used as cut-off. Three-months survival of Status 2A was 70.2%. However, in Status 2A patients whose MELD score less than 24 (n=82), 86.6% of patients survived until 6 month. Furthermore, patients with high MELD score (> or =31) among Status 2B group showed poorer survival rate (45.8%, 3-month) than Status 2A group. In conclusion, MELD score-based system can predict short term mortality better and select more number of high risk patients in Korean population.
Area Under Curve
;
Cohort Studies
;
End Stage Liver Disease/*mortality/therapy
;
Humans
;
*Liver Transplantation
;
*Models, Statistical
;
ROC Curve
;
Registries
;
*Severity of Illness Index
;
Survival Rate
;
Time Factors
;
Waiting Lists
2.Pre-transplant Predictors for 3-Month Mortality after Living Donor Liver Transplantation.
Nuri LEE ; Jong Man KIM ; Choon Hyuck David KWON ; Jae Won JOH ; Dong Hyun SINN ; Joon Hyeok LEE ; Mi Sook GWAK ; Seung Woon PAIK ; Suk Koo LEE
The Journal of the Korean Society for Transplantation 2014;28(4):226-235
BACKGROUND: High model for end-stage liver disease (MELD) scores (> or =35) is closely associated with poor posttransplantation outcomes in patients who undergo living donor liver transplantation (LDLT). There is little information regarding factors that negatively impact the survival of patients with high MELD scores. The aim of this study was to identify factors associated with 3-month mortality of patients after LDLT. METHODS: We retrospectively analyzed 774 patients who underwent adult LDLT with right lobe grafts between 1996 and 2012. Exclusion criteria were re-transplantation, left graft, auxiliary partial orthotopic liver transplantation, and inadequate medical recording. Preoperative variables were analyzed retrospectively. RESULTS: The overall 3-month survival rate was 92%. In univariate analysis, acute progression of disease, severity of hepatic encephalopathy, Child-Pugh class C, hepatorenal syndrome, use of continuous renal replacement therapy, use of ventilator, intensive care unit (ICU) care before transplantation, and MELD scores > or =35 were identified as potential risk factors. However, only ICU care before transplantation and MELD scores > or =35 were independent risk factors for 3-month mortality after LDLT. Three-month and 1-year patient survival rates for those with no risk factors were 95.5% and 88.6%, respectively. In contrast, patients with at least one risk factor had 3-month and 1-year patient survival rates of 88.4% and 81.1%, respectively, while patients with two risk factors had 3-month and 1-year patient survival rates of 55.6% and 55.6%, respectively. CONCLUSIONS: Patients with both risk factors (ICU care before LDLT and MELD scores > or =35) should be cautiously considered for treatment with LDLT.
Adult
;
End Stage Liver Disease
;
Hepatic Encephalopathy
;
Hepatorenal Syndrome
;
Humans
;
Intensive Care Units
;
Liver Diseases
;
Liver Transplantation*
;
Living Donors*
;
Medical Records
;
Mortality*
;
Renal Replacement Therapy
;
Retrospective Studies
;
Risk Factors
;
Survival Rate
;
Transplants
;
Ventilators, Mechanical
3.Pediatric Liver Transplantation Outcomes in Korea.
Jong Man KIM ; Kyung Mo KIM ; Nam Joon YI ; Yon Ho CHOE ; Myung Soo KIM ; Kyung Suk SUH ; Soon Il KIM ; Suk Koo LEE ; Sung Gyu LEE
Journal of Korean Medical Science 2013;28(1):42-47
Pediatric liver transplantation is the standard of care for treatment of liver failure in children. The aim of this study was to identify the characteristics of pediatric liver transplantation in centers located in Korea and determine factors that influence outcomes. This retrospective study was performed using data from between 1988 and 2010 and included all recipients 18 yr old and younger who underwent pediatric liver transplantation in Korea during that period. Our data sources were hospital medical records and the outcome measure was overall patient survival. Univariate and multivariate statistical analyses were undertaken using the Cox proportional hazards model. Five hundred and thirty-four pediatric liver transplantations were performed in 502 children. Median age and average pediatric end-stage liver disease (PELD) score were 20 months and 18 point, respectively. Biliary atresia (57.7%, 308/534) was the most common cause of liver disease. Eighty-two (15.3%) were deceased donor liver transplantations and 454 (84.7%) were living donor liver transplantations. Retransplantation was performed in 32 cases (6%). Overall, 1-, 5-, and 10-yr patient survival rates were 87.8%, 82.2%, and 78.1%, respectively. In multivariate analysis, independent significant predictors of poor patient survival were chronic rejection and retransplantation. This study presents the epidemiologic data for nearly all pediatric liver transplantation in Korea and shows that the independent prognostic factors in patient survival are chronic rejection and retransplantation.
Adolescent
;
Biliary Atresia/epidemiology
;
Child
;
Child, Preschool
;
End Stage Liver Disease/epidemiology/mortality/*therapy
;
Female
;
Graft Survival
;
Humans
;
Infant
;
*Liver Transplantation
;
Male
;
Prognosis
;
Proportional Hazards Models
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Severity of Illness Index
;
Survival Rate
;
Treatment Outcome
4.Efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load.
Lu-biao CHEN ; Hong CAO ; Yu-feng ZHANG ; Xin SHU ; Ni CHEN ; Ka ZHANG ; Gang LI ; Qi-huan XU
Chinese Journal of Experimental and Clinical Virology 2010;24(5):364-366
OBJECTIVETo investigate the efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load.
METHODS352 patients with acute-on-chronic hepatitis B liver failure including 175 cases of low HBV viral load and 177 cases of high HBV viral load were enrolled into this study. The patients were divided into the antiviral group which received antiviral therapy (Lamivudine, Entecavir or Telbivudine) plus routine supportive therapy and the control group which received supportive therapy only. The clinical features and the 24-week short-term efficacy of antiviral therapy were assessed.
RESULTSAt week 24,total survival rate in antiviral group was higher than that in control group (P = 0.010). The survival rate of patients with low viral load in the antiviral group was higher than that in the control group (P = 0.001). But there was no significant difference between the antiviral group and the control group with high viral load (P = 0.856). But in the antiviral group, there was no significant difference in survival rate between the patients with high HBV viral load and those with low viral load (P = 0.755).
CONCLUSIONSAntiviral therapy can significantly improve survival rate of patients of acute-on-chronic hepatitis B liver failure with low viral load. Liver failure;
Adult ; Antiviral Agents ; therapeutic use ; End Stage Liver Disease ; drug therapy ; mortality ; virology ; Female ; Guanine ; analogs & derivatives ; therapeutic use ; Hepatitis B, Chronic ; drug therapy ; mortality ; virology ; Humans ; Lamivudine ; therapeutic use ; Liver Failure, Acute ; drug therapy ; mortality ; virology ; Male ; Middle Aged ; Nucleosides ; therapeutic use ; Pyrimidinones ; therapeutic use ; Thymidine ; analogs & derivatives ; Viral Load ; drug effects